Sara García-Davis

Dr. Sara García-Davis

University of La Laguna, San Cristóbal de La Laguna, Spain
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2018 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Sara García-DavisSara García-Davis
Sara García-Davis
ines sifaouiines sifaoui
ines sifaoui
MRMaría Reyes-Batlle
María Reyes-Batlle
EVEzequiel Viveros-Valdez
Ezequiel Viveros-Valdez
Jose E. PiñeroJose E. Piñero
Jose E. Piñero
Ana R. Diaz-MarreroAna R. Diaz-Marrero
Ana R. Diaz-Marrero
Focused on our interest to develop novel antiparasistic agents, the present study was aimed to evaluate the biological activity of an extract of Laurencia johnstonii collected in Baja California Sur, Mexico, against an Acantamoeba castellanii Neff strain. Bioassay-guided fractionation allowed us to identify the amoebicidal diastereoisomers α-bromocuparane (4) and α-isobromocuparane (5). Furthermore, bromination of the inactive laurinterol (1) and isolaurinterol (2) yielded four halogenated derivatives, (6)–(9), which improved the activity of the natural sesquiterpenes. Among them, the most active compound was 3α-bromojohnstane (7), a sesquiterpene derivative which possesses a novel carbon skeleton johnstane.

20 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IAIñigo Arberas-Jiménez
Iñigo Arberas-Jiménez
Sara García-DavisSara García-Davis
Sara García-Davis
ARAitor Rizo-Liendo
Aitor Rizo-Liendo
ISInes Sifaoui
Ines Sifaoui
MRMaría Reyes-Batlle
María Reyes-Batlle
Jacob Lorenzo-MoralesJacob Lorenzo-Morales
Jacob Lorenzo-Morales
Primary amoebic encephalitis (PAM) is a lethal disease caused by the opportunistic pathogen, Naegleria fowleri. This amoebic species is able to live freely in warm aquatic habitats and to infect children and young adults when they perform risk activities in these water bodies such as swimming or splashing. Besides the need to increase awareness of PAM which will allow an early diagnosis, the development of fully effective therapeutic agents is needed. Current treatment options are amphotericin B and miltefosine which are not fully effective and also present toxicity issues. In this study, the in vitro activity of various sesquiterpenes isolated from the red alga Laurencia johnstonii were tested against the trophozoite stage of a strain of Naegleria fowleri. Moreover, the induced effects (apoptotic cell death) of the most active compound, laurinterol (1), was evaluated by measuring DNA condensation, damages at the mitochondrial level, cell membrane disruption and production of reactive oxygen species (ROS). The obtained results demonstrated that laurinterol was able to eliminate the amoebae at concentrations of 13.42 ± 2.57 µM and also to induced programmed cell death (PCD) in the treated amoebae. Moreover, since ATP levels were highly affected and laurinterol has been previously reported as an inhibitor of the Na+/K+-ATPase sodium–potassium ion pump, comparison with known inhibitors of ATPases were carried out. Our results points out that laurinterol was able to inhibit ENA ATPase pump at concentrations 100 times lower than furosemide.

29 March 2019 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Sara García-DavisSara García-Davis
Sara García-Davis
EVEzequiel Viveros-Valdez
Ezequiel Viveros-Valdez
Ana R. Diaz-MarreroAna R. Diaz-Marrero
Ana R. Diaz-Marrero
José J. FernándezJosé J. Fernández
José J. Fernández
DVDaniel Valencia-Mercado
Daniel Valencia-Mercado
NDNancy Elena Guzman Delgado
Nancy Elena Guzman Delgado
Macroalgae represent an important source of bioactive compounds with a wide range of biotechnological applications. Overall, the discovery of effective cytotoxic compounds with pharmaceutical potential is a significant challenge, mostly because they are scarce in nature or their total synthesis is not efficient, while the bioprospecting models currently used do not predict clinical responses. Given this context, we used three-dimensional (3D) cultures of human breast cancer explants to evaluate the antitumoral effect of laurinterol, the major compound of an ethanolic extract of Laurencia johnstonii. To this end, we evaluated the metabolic and histopathological effects of the crude extract of L. johnstonii and laurinterol on Vero and MCF-7 cells, in addition to breast cancer explants. We observed a dose-dependent inhibition of the metabolic activity, as well as morphologic and nuclear changes characteristic of apoptosis. On the other hand, a reduced metabolic viability and marked necrosis areas were observed in breast cancer explants incubated with the crude extract, while explants treated with laurinterol exhibited a heterogeneous response which was associated with the individual response of each human tumor sample. This study supports the cytotoxic and antitumoral effects of laurinterol in in vitro cell cultures and in ex vivo organotypic cultures of human breast cancer explants.

30 May 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Sara García-DavisSara García-Davis
Sara García-Davis
KLKarla Leal-López
Karla Leal-López
CMCarmen Molina-Torres
Carmen Molina-Torres
LVLucio Vera-Cabrera
Lucio Vera-Cabrera
Ana R. Diaz-MarreroAna R. Diaz-Marrero
Ana R. Diaz-Marrero
EVEzequiel Viveros-Valdez
Ezequiel Viveros-Valdez
Marine environments represent a great opportunity for the discovery of compounds with a wide spectrum of bioactive properties. Due to their large variety and functions derived from natural selection, marine natural products may allow the identification of novel drugs based not only on newly discovered bioactive metabolites but also on already known compounds not yet thoroughly investigated. Since drug resistance has caused an increase in infections by Mycobacterium tuberculosis and nontuberculous mycobacteria, the re-evaluation of known bioactive metabolites has been suggested as a good approach to addressing this problem. In this sense, this study presents an evaluation of the in vitro effect of laurinterol and aplysin, two brominated sesquiterpenes isolated from Laurencia johnstonii, against nine M. tuberculosis strains and six nontuberculous mycobacteria (NTM). Laurinterol exhibited good antimycobacterial activity, especially against nontuberculous mycobacteria, being remarkable its effect against Mycobacterium abscessus, with minimum inhibitory concentration (MIC) values lower than those of the reference drug imipenem. This study provides further evidence for the antimycobacterial activity of some sesquiterpenes from L. johnstonii, which can be considered interesting lead compounds for the discovery of novel molecules to treat NTM infections.

30 May 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Sara García-DavisSara García-Davis
Sara García-Davis
ALAtteneri López-Arencibia
Atteneri López-Arencibia
CBCarlos J. Bethencourt-Estrella
Carlos J. Bethencourt-Estrella
DNDesirée San Nicolás-Hernández
Desirée San Nicolás-Hernández
EVEzequiel Viveros-Valdez
Ezequiel Viveros-Valdez
Jose E. PiñeroJose E. Piñero
Jose E. Piñero
Among neglected tropical diseases, leishmaniasis is one of the leading causes, not only of deaths but also of disability-adjusted life years. This disease, caused by protozoan parasites of the genus Leishmania, triggers different clinical manifestations, with cutaneous, mucocutaneous, and visceral forms. As existing treatments for this parasitosis are not sufficiently effective or safe for the patient, in this work, different sesquiterpenes isolated from the red alga Laurencia johnstonii have been studied for this purpose. The different compounds were tested in vitro against the promastigote and amastigote forms of Leishmania amazonensis. Different assays were also performed, including the measurement of mitochondrial potential, determination of ROS accumulation, and chromatin condensation, among others, focused on the detection of the cell death process known in this type of organism as apoptosis-like. Five compounds were identified that displayed leishmanicidal activity: laurequinone, laurinterol, debromolaurinterol, isolaurinterol, and aplysin, showing IC50 values against promastigotes of 1.87, 34.45, 12.48, 10.09, and 54.13 µM, respectively. Laurequinone was the most potent compound tested and was shown to be more effective than the reference drug miltefosine against promastigotes. Different death mechanism studies carried out showed that laurequinone appears to induce programmed cell death or apoptosis in the parasite studied. The obtained results underline the potential of this sesquiterpene as a novel anti-kinetoplastid therapeutic agent.

11 March 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
IAIñigo Arberas-Jiménez
Iñigo Arberas-Jiménez
Sara García-DavisSara García-Davis
Sara García-Davis
ARAitor Rizo-Liendo
Aitor Rizo-Liendo
ISInes Sifaoui
Ines Sifaoui
EMEzequiel Q. Morales
Ezequiel Q. Morales
José J. FernándezJosé J. Fernández
José J. Fernández
Primary amoebic meningoencephalitis (PAM) is a central nervous system (CNS) disease caused by Naegleria fowleri that mainly affects children and young adults with fatal consequences in most of the cases. Treatment protocols are based on the combination of different antimicrobial agents, nonetheless there is the need to develop new anti-Naegleria compounds with low toxicity and full effects compared to the currently used drug combination. The marine environment is a well-established source of bioactive natural products. In this work, we have focused on the structure of Laurencia cyclolaurane-type sesquiterpenes as potential chemical model against Naegleria species. The effects of debromolaurinterol (1) to induce PCD/apoptosis-like events in Naegleria fowleri have been evaluated, revealing that this compound induced reduction of ATP production showing a decrease of 99.98% in treated parasite cells. A SAR analysis have been supported with molecular modeling and analysis of the in silico ADME/Tox properties of the Laurencia sesquiterpenes debromolaurinterol (1), laurinterol (2) and allolaurinterol (3), which reinforce cyclolaurane metabolites as plausible molecular models to develop PAM treatments.